ecancermedicalscience

Case Report

Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma

24 Nov 2008
T De Pas, G Spitaleri, P Della Vigna, F Toffalorio, G Curigliano, A Gambino, S Boselli, F De Braud

Background: despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free survival and overall survival compared to GCB alone in patients with soft-tissue sarcoma, GCB mono-chemotherapy should be considered as a preferable option with respect to the combination because of its lower toxicity profile and the possibility of it being administered continuously for a long time period.

Case report: we report a clinical case of a woman with advanced high-grade uterine leiomyosarcoma, refractory to ifosfamide, doxorubicin and trabectedin, who experienced a sustained and progressive response to GCB alone.

Conclusions: GCB given as mono-chemotherapy can obtain long-lasting tumour control in patients heavily pre-treated with various chemotherapeutic regimes for uterine LMS and should be considered as a possible option for this subset of patients.

Keywords:
Gemcitabine; second-line chemotherapy; refractory uterine leiomyosarcoma

Article metrics: 501 views
159
342

Related Articles

Muhammad Shahid Iqbal, Joseph Carlow, Fiona McDonald, Philip Atherton, Helen Turnbull, Sandeep Singhal, Timothy Simmons, Paula Mulvenna, Josef Kovarik, Rhona McMenemin, Jill Gardiner, Alastair Greystoke
Tiago Cordeiro Felismino, Victor Hugo Fonseca de Jesus, Bruno Cezar de Mendonça Uchóa Junior, Francisca Giselle Rocha Moura, Rachel P Riechelmann, Samuel Aguiar Junior, Celso Abdon Lopes de Mello
Małgorzata Sawicka-Żukowska, Włodzimierz Łuczyński, Jakub Dobroch, Maryna Krawczuk-Rybak